The two parent hormones
Amycretin is built on two natural hormones, so understanding the drug means understanding them first.
The satiety hormone and the incretin
Amycretin is built on two natural hormones, so understanding the drug means understanding them first. Amylin is a fullness signal from the pancreas; GLP-1 is an incretin from the gut. Both curb appetite, but through different receptors and circuits.
This unit covers the biology amycretin fuses together: what each hormone does, the unusual receptor amylin uses, and the "amyloid" problem that made copying amylin surprisingly hard.
Key terms
Two hormones, two jobs
Amylin and GLP-1 are both released after a meal and both help end eating, but they come from different places and use different receptors. Amylin is co-secreted with insulin from the pancreas; GLP-1 is an incretin released from intestinal cells. Amycretin fuses copies of both into one molecule.
Because they act through separate receptors, the amylin receptor built on the calcitonin receptor and the GLP-1 receptor, their effects can add together rather than simply overlap, and in trials CagriSema, which pairs semaglutide with the amylin analogue cagrilintide, has achieved greater effects than either drug alone. That complementarity is the scientific bet behind amycretin: two appetite brakes engaged by one molecule should push weight loss beyond what a pure GLP-1 drug achieves.
AdvancedWhy the two hormones work as partners
Both hormones are part of the body's post-meal program. GLP-1 is released from gut cells after nutrient intake, and amylin is co-secreted with insulin from the pancreas in response to nutrients; one review describes amylin as complementing insulin by controlling how fast nutrients appear in the blood. Copying both is therefore not a random pairing but a way to recruit two parts of the same post-meal response.